Catalogued systematically as 1-{[(9H-fluoren-9-ylmethoxy)carbonyl]oxy}pyrrolidine-2,5-dione, the compound is functionally recognized as Fmoc-OSu, the succinimidyl ester of the base-labile 9-fluorenylmethyloxycarbonyl protecting group. With CAS registry 82911-69-1 and a molecular formula of C19H15NO5 (molecular weight 337.33 g·mol⁻¹), this white to off-white crystalline powder serves as the primary acylation vehicle for introducing the Fmoc moiety onto the α-amine of proteinogenic and non-proteinogenic amino acids. Its design displaces the need for handling the volatile, shelf-unstable Fmoc chloride in contemporary peptide synthesis workflows.
Why is Fmoc-OSu Routinely Preferred Over Fmoc Chloride for Solution-Phase Derivatization?
When amino acid Nα-protection is executed in aqueous-organic biphasic systems, the hydrolysis rate of the reagent becomes the critical process variable. Fmoc chloride, still encountered in legacy protocols, hydrolyzes rapidly at pH values above 7.0, forming the unreactive N-(9-fluorenylmethyl)carbamic acid and dibenzofulvene via β-elimination. This side pathway consumes the reagent and generates fulvene adducts that co-elute with the protected amino acid during reversed-phase HPLC monitoring. Under identical biphasic conditions (dioxane/10% Na2CO3, 0–5 °C), the succinimidyl carbonate ester resists nucleophilic degradation for a sufficient processing window—its half-life in 0.1 M aqueous carbonate at 0 °C exceeds 45 minutes, compared to less than 8 minutes for Fmoc-Cl. This kinetic differential permits controlled stoichiometry of 1.05–1.15 equivalents relative to the free amine, minimizing over-acylation and the need for post-reaction extraction of dibenzofulvene derivatives. Production-scale batches conducted in jacketed stirred-tank reactors with bottom-drain valves on 100–500 L scale routinely achieve ≥ 97% isolated yield of Fmoc-amino acids after a single trituration with methyl tert-butyl ether.
No separate header precedes the discussion of reagent physical form, allowing this paragraph to open the handling comparison directly. Fmoc-OSu is delivered as a free-flowing crystalline solid with a bulk density that permits accurate gravimetric dispensing on analytical balances with 0.1 mg readability. Fmoc chloride, in contrast, is a low-melting solid (mp 62–64 °C) that sinters under ambient storage and requires solvent transfer for reproducible charge. The succinimidyl ester melts sharply at 150–155 °C (determined by differential scanning calorimetry per ASTM E794 at 10 °C·min⁻¹ heating rate) with no decomposition exotherm until above 180 °C, a thermal profile compatible with standard laboratory heating blocks during solvent evaporation post-coupling.
Purity Specification Thresholds and Their Cascade Effect on Peptide Crude Profiles
Automated solid-phase peptide synthesis (SPPS) operating with Fmoc/tBu chemistry is exceptionally sensitive to the purity of the incoming Fmoc protection reagent. A single condensation cycle on a resin-bound amine utilizes the Fmoc-amino acid rather than free Fmoc-OSu, but the preparation of those Fmoc-amino acid synthons is where the reagent’s trace impurity profile becomes embedded. The accompanying table maps the key quality parameters measured against standard analytical methods.
| Parameter | Specification Limit | Analytical Method | Impact of Off-Spec Value |
|---|---|---|---|
| Assay (anhydrous, non-aqueous titration) | ≥ 99.0% (w/w) | Perchloric acid titration in acetic acid, potentiometric endpoint | Under-charge of Fmoc-OSu leads to incomplete amine protection; residual free amino acid reacts in subsequent coupling cycles, generating deletion sequences. |
| Water content | ≤ 0.30% | Karl Fischer coulometry, ASTM E203 | Water hydrolyzes the active ester to Fmoc-OH, which does not acylate the amine. Each 0.1% water increase reduces effective reagent molarity by approximately 0.3%, requiring empirical excess adjustment. |
| Dibenzofulvene (DBF) content | ≤ 0.50% (area %) | HPLC, C18 column, UV 266 nm, isocratic acetonitrile/water 70:30 | Pre-existing DBF forms adducts with the amine component, generating a piperidine-stable impurity that cannot be removed by washing and persists into the final peptide. |
| Melting point | 150–155 °C | Capillary method or DSC ASTM E794 | Depression below 148 °C indicates residual solvent (typically ethyl acetate or THF) or incomplete drying, correlating with inaccurate gravimetric assay. |
In peptide facilities operating under cGMP (21 CFR Part 210/211), a supplier’s certificate of analysis must reference an HPLC purity method that resolves Fmoc-β-alanine, a known rearrangement byproduct of the succinimidyl ester at elevated pH, from the main peak. Resolution of at least 2.0 between Fmoc-OSu and Fmoc-β-Ala-OH on a 150 × 4.6 mm, 3 µm C18 column is a typical acceptance criterion. Failure to control this impurity adds a β-alanine-terminated truncation to the peptide product, detected only by high-resolution mass spectrometry.
Assessing Shelf-Life Under Tropical Storage Conditions
Moisture ingress is the dominant degradation vector. Long-term stability data generated at 25 °C / 60% RH in sealed laminated aluminum pouches with desiccant sachets demonstrate assay retention above 99.0% over 24 months. Once the container is opened and the reagent is exposed to ambient humidity exceeding 50% RH, a measurable increase in free Fmoc-OH is detected within 72 hours by thin-layer chromatography (silica gel 60 F254, ethyl acetate/hexane 1:1). In facilities located in equatorial zones without controlled humidity suites, it is common practice to sub-aliquot the material into single-use vials under dry nitrogen in a glovebox maintaining < 10 ppm H2O prior to freezer storage at -20 °C. Re-warming to ambient temperature must be performed in a still-sealed container to prevent condensation; a 1 kg container requires approximately 4 hours to equilibrate before opening without surface moisture formation.
Synthetic peptide production on microwave-assisted synthesizers (CEM Liberty Blue or Biotage Initiator+ Alstra) adds a thermal stress dimension. In pre-activation protocols where Fmoc-amino acids are generated in situ from the free amino acid and Fmoc-OSu in dimethylformamide at 50 °C, the reagent demonstrates thermal stability with less than 2% degradation after 30 minutes, as monitored by inline UV at 301 nm. However, combination with the hindered base N-methylmorpholine must be strictly sequential; simultaneous addition of base and Fmoc-OSu to the amino acid solution promotes rapid formation of the Fmoc-β-alanine rearrangement impurity, reaching 5–8% within 5 minutes. The prescribed order of addition is: dissolve amino acid and 1.0 equivalent of N-methylmorpholine, then add Fmoc-OSu in a single portion. This stands in contrast to Fmoc-Cl, which demands inverse addition (reagent to base) to avoid uncontrolled exotherms.
Differentiation from 9-Fluorenylmethyl Succinimidyl Carbonate and Other Fmoc Donors
The nomenclature similarity between Fmoc-OSu and 9-fluorenylmethyl succinimidyl carbonate (Fmoc-OSu is technically a carbonate, as the Fmoc oxygen attaches to the carbonyl forming a mixed carbonate with succinimide) requires clarification: the compound is a single defined chemical entity, not a mixture of isomers. Confusion sometimes arises with Fmoc-OBt (1-{[(9H-fluoren-9-ylmethoxy)carbonyl]oxy}benzotriazole), which is the benzotriazolyl analog. Fmoc-OBt exhibits higher reactivity due to the better leaving-group ability of the benzotriazole anion (pKa of HOBt ≈ 4.6 versus pKa of HOSu ≈ 6.0), but its preparation is less atom-economical and the reagent is less crystalline, complicating purification. Fmoc-OSu is the intermediate of choice when the mildest stable active ester is required, particularly for amino acids bearing side-chain functionalities sensitive to nucleophilic catalysis (e.g., the γ-carboxyl of Fmoc-Glu-OtBu, where OBt esters can promote pyroglutamate formation).
In the context of orthogonal protection schemes, Boc-OSu (tert-butyl succinimidyl carbonate) is the acid-labile counterpart used in Boc-SPPS. Fmoc-OSu-generated protection withstands the trifluoroacetic acid cocktail used for side-chain deprotection and cleavage in Fmoc chemistry, while the Boc group is removed simultaneously under those conditions. This orthogonality is the structural basis for the widespread adoption of the Fmoc strategy in multi-kilogram production of generic therapeutic peptides such as leuprolide and goserelin. Process fits for these APIs routinely employ Fmoc-OSu-derived Fmoc-Leu-OH and Fmoc-Ser(tBu)-OH in fragment condensations on 50–200 mmol scale, where the crystalline nature of the reagent supports direct addition via solid dispensing systems without the line blockages experienced with hygroscopic oils.
